NPORT-EX 2 NPORT_5836598429612311.htm BlackRock Health Sciences Trust

Schedule of Investments  (unaudited)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

 

Biotechnology — 20.8%  

Acceleron Pharma, Inc.(a)(b)

     38,131     $ 4,290,881  

Acerta Pharma BV, Series B, (Acquired 2/01/2016, Cost: $986,402)(c)(d)

     17,146,440       2,294,537  

Agios Pharmaceuticals, Inc.(a)(b)

     25,150       880,250  

Alexion Pharmaceuticals, Inc.(a)(b)

     26,878       3,075,650  

Allakos, Inc.(a)(b)

     31,025       2,526,986  

Allogene Therapeutics, Inc.(a)(b)

     30,786       1,160,940  

Alnylam Pharmaceuticals, Inc.(a)(b)

     31,968       4,654,541  

Amgen, Inc.(a)

     55,218       14,034,207  

Annexon, Inc.(b)

     16,780       507,259  

Apellis Pharmaceuticals, Inc.(a)(b)

     22,450       677,316  

Arcutis Biotherapeutics, Inc.(b)(e)

     5,322       155,935  

Arena Pharmaceuticals, Inc.(a)(b)

     18,854       1,410,091  

Atreca, Inc., Class A(b)

     19,453       271,758  

Biogen, Inc.(a)(b)

     10,940       3,103,459  

BioMarin Pharmaceutical, Inc.(a)(b)

     34,556       2,629,020  

Blueprint Medicines Corp.(a)(b)

     9,623       892,052  

ChemoCentryx, Inc.(a)(b)

     5,100       279,480  

Dicerna Pharmaceuticals, Inc.(a)(b)

     14,790       266,072  

Eidos Therapeutics, Inc.(a)(b)

     8,058       407,171  

FibroGen, Inc.(a)(b)

     5,980       245,898  

Galapagos NV, ADR(a)(b)

     5,792       821,943  

Genfit , ADR(b)

     1,238       6,586  

Genmab A/S(b)

     14,763       5,357,574  

Genmab A/S, ADR(a)(b)

     48,661       1,781,479  

Gilead Sciences, Inc.(a)

     76,057       4,806,042  

Halozyme Therapeutics, Inc.(a)(b)

     25,850       679,338  

Humanigen, Inc.(b)(e)

     20,679       220,025  

Immunomedics, Inc.(a)(b)

     32,291       2,745,704  

Immunovant, Inc.(b)

     35,971       1,265,819  

Incyte Corp.(a)(b)

     23,637       2,121,184  

Intellia Therapeutics, Inc.(a)(b)

     13,519       268,758  

Iovance Biotherapeutics, Inc.(a)(b)

     30,890       1,016,899  

Kodiak Sciences, Inc.(a)(b)

     9,010       533,482  

Krystal Biotech, Inc.(b)

     5,200       223,860  

Mersana Therapeutics, Inc.(a)(b)

     57,220       1,065,436  

Mirati Therapeutics, Inc.(a)(b)

     5,271       875,250  

Molecular Templates, Inc.(a)(b)

     21,176       231,242  

Neurocrine Biosciences, Inc.(a)(b)

     21,162       2,034,938  

Passage Bio, Inc.(b)

     8,140       106,715  

Prothena Corp. PLC(a)(b)

     21,000       209,790  

Rapt Therapeutics, Inc.(b)

     8,660       278,852  

Regeneron Pharmaceuticals, Inc.(a)(b)

     12,485       6,988,853  

Relay Therapeutics, Inc.(b)

     10,918       464,998  

Sarepta Therapeutics, Inc.(a)(b)

     8,718       1,224,269  

Seattle Genetics, Inc.(a)(b)

     62,768       12,283,070  

Seres Therapeutics, Inc.(a)(b)

     26,200       741,722  

Taysha Gene Therapies, Inc.(b)

     13,722       307,373  

TCR2 Therapeutics, Inc.(a)(b)

     10,160       206,451  

Vertex Pharmaceuticals, Inc.(a)(b)

     41,693       11,345,499  

Vir Biotechnology, Inc.(a)(b)

     7,660       262,968  
   

 

 

  
      104,239,622  
Diversified Financial Services(b) — 0.4%            

ARYA Sciences Acquisition Corp. II

     12,589       138,479  

ARYA Sciences Acquisition Corp. III, Class A

     16,560       177,523  

BCTG Acquisition Corp

     8,720       94,525  

Deerfield Healthcare Technology Acquisitions Corp

     21,007       223,304  

FS Development Corp., Class A

     16,513       184,946  
Security   Shares     Value  
Diversified Financial Services (continued)            

Health Sciences Acquisitions Corp

     13,696     $ 150,656  

Longview Acquisition Corp

     35,345       358,752  

Panacea Acquisition Corp

     12,152       145,824  

Therapeutics Acquisition Corp., Class A

     27,000       388,260  
   

 

 

  
      1,862,269  
Health Care Equipment & Supplies — 30.3%            

Abbott Laboratories(a)

     236,025       25,686,601  

ABIOMED, Inc.(a)(b)

     10,647       2,949,858  

Alcon AG(a)(b)

     115,493       6,577,326  

Baxter International, Inc.(a)

     125,666       10,106,060  

Becton Dickinson and Co.(a)

     30,953       7,202,144  

Boston Scientific Corp.(a)(b)

     366,053       13,986,885  

Edwards Lifesciences Corp.(a)(b)

     157,245       12,551,296  

Envista Holdings Corp.(b)

     36,720       906,250  

Intuitive Surgical, Inc.(a)(b)

     14,158       10,045,667  

Kangji Medical Holdings Ltd., (Acquired 06/22/2020, Cost: $479,242)(b)(d)

     264,936       650,177  

Masimo Corp.(a)(b)

     29,400       6,940,164  

Medtronic PLC(a)

     140,686       14,620,089  

Nevro Corp.(a)(b)

     13,352       1,859,934  

ResMed, Inc.(a)

     25,314       4,339,579  

SI-BONE, Inc.(b)

     4,237       100,502  

Silk Road Medical, Inc.(a)(b)

     9,292       624,515  

Straumann Holding AG, Registered Shares

     2,500       2,529,003  

Stryker Corp.(a)

     59,696       12,438,855  

Teleflex, Inc.(a)

     19,140       6,515,639  

Varian Medical Systems, Inc.(b)

     39,799       6,845,428  

Zimmer Biomet Holdings, Inc.(a)

     30,125       4,101,217  
   

 

 

  
      151,577,189  
Health Care Providers & Services — 18.4%            

Amedisys, Inc.(a)(b)

     19,072       4,509,193  

AmerisourceBergen Corp.(a)

     14,280       1,384,018  

Anthem, Inc.(a)

     37,297       10,017,601  

Cardinal Health, Inc.(a)

     25,630       1,203,328  

Centene Corp.(a)(b)

     83,954       4,897,037  

Cigna Corp.(a)

     53,197       9,012,104  

Encompass Health Corp.(a)

     40,167       2,610,052  

Humana, Inc.(a)

     29,780       12,325,644  

LHC Group, Inc.(a)(b)

     20,224       4,298,813  

McKesson Corp.(a)

     6,180       920,387  

Oak Street Health, Inc.(b)

     8,409       449,377  

Oak Street Health Inc., (Acquired 03/04/2020, Cost: $575,147)(d)

     54,700       2,821,669  

Quest Diagnostics, Inc.(a)

     12,824       1,468,220  

UnitedHealth Group, Inc.(a)(f)

     115,262       35,935,234  
   

 

 

  
      91,852,677  
Health Care Technology(b) — 0.9%            

GoodRx Holdings, Inc., Class A

     5,858       325,705  

Livongo Health, Inc.(a)

     8,920       1,249,246  

Teladoc Health, Inc.(a)

     13,170       2,887,391  
   

 

 

  
      4,462,342  
Insurance(b) — 0.1%            

GoHealth, Inc., Class A

     36,551       476,077  

Selectquote, Inc.(a)

     9,800       198,450  
   

 

 

  
      674,527  
Life Sciences Tools & Services — 7.7%            

Agilent Technologies, Inc.(a)

     13,960       1,409,122  

Avantor, Inc.(a)(b)

     131,114       2,948,754  
 

 

 

SCHEDULE OF INVESTMENTS

   1

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Life Sciences Tools & Services (continued)            

Illumina, Inc.(a)(b)

     14,172     $ 4,380,282  

IQVIA Holdings, Inc.(a)(b)

     25,673       4,046,835  

PPD, Inc.(a)(b)

     79,280       2,932,567  

Thermo Fisher Scientific, Inc.(a)

     37,181       16,416,155  

WuXi AppTec Co. Ltd., Class H(g)

     225,785       3,265,024  

Wuxi Biologics Cayman, Inc.(b)(g)

     120,500       2,953,221  
   

 

 

  
      38,351,960  
Pharmaceuticals — 20.7%            

AstraZeneca PLC

     15,836       1,730,311  

Bristol-Myers Squibb Co.(a)

     167,123       10,075,846  

Eisai Co. Ltd

     30,500       2,785,635  

Eli Lilly & Co.(a)

     75,883       11,232,202  

Hansoh Pharmaceutical Group Ltd.(b)(g)

     882,438       4,313,037  

Hua Medicine(b)(e)(g)

     735,105       473,310  

Johnson & Johnson(a)

     157,637       23,468,996  

Merck & Co., Inc.(a)

     103,567       8,590,883  

Merck KGaA

     25,216       3,676,300  

MyoKardia, Inc.(a)(b)

     6,691       912,184  

Nektar Therapeutics(a)(b)

     24,513       406,671  

Ocumension Therapeutics, (Acquired 07/06/2020, Cost: $65,918)(b)(d)(g)

     34,500       100,999  

Pfizer, Inc.(a)

     324,195       11,897,956  

Roche Holding AG

     12,627       4,325,260  

Royalty Pharma PLC, Class A(a)

     15,446       649,813  

Sanofi

     68,455       6,860,000  

Sanofi, ADR(a)

     54,625       2,740,536  

Zoetis, Inc.(a)

     54,489       9,010,846  
   

 

 

  
      103,250,785  
   

 

 

  

Total Common Stocks — 99.3%
(Cost: $305,458,953)

       496,271,371  
   

 

 

  
    

Par

(000)

         

Corporate Bonds

    
Biotechnology — 0.1%            

Kronos Bio, Inc, (Acquired: 08/20/2020, Cost: $260,000), 0.00%, 02/14/22(c)(d)(h)

   $ 260       260,000  
   

 

 

  

Total Corporate Bonds — 0.1%
(Cost: $260,000)

       260,000  
   

 

 

  
     Benefical
Interest
(000)		         

Other Interests

    
Pharmaceuticals — 0.0%            

Afferent Pharmaceuticals, Inc.(c)(i)

   $ 190       252,913  
   

 

 

  

Total Other Interests — 0.0%
(Cost:$—)

       252,913  
   

 

 

  
     Shares         

Preferred Securities

    
Preferred Stocks — 0.5%            
Biotechnology — 0.5%            

Annexon, Inc., Series D, (Acquired 06/26/2020, Cost:$190,006)(d)

     15,164       444,146  

Arcutis Biotherapeutics, Inc

     37,056       1,085,741  
Security   Shares     Value  
Biotechnology (continued)            

Goldfinch Bio, Inc., Series B, (Acquired 06/26/2020, Cost: $149,465)(c)(d)

     126,665     $ 149,465  

Sigilon Therapeutics, Inc., Series B, (Acquired 02/14/2020, Cost: $264,000)(c)(d)

     44,000       266,200  

Taysha Gene Therapies, Inc., Series B, (Acquired 07/30/2020, Cost: $268,600)(d)

     17,214       366,956  
   

 

 

  

Total Preferred Securities — 0.5%
(Cost: $1,303,168)

       2,312,508  
   

 

 

  

Total Long-Term Investments — 99.9%
(Cost: $307,022,121)

       499,096,792  
   

 

 

  

Short-Term Securities

    

Money Market Funds — 1.3%

    

BlackRock Liquidity Funds, T-Fund, Institutional Class,
0.02%(i)(j)

     6,247,858       6,247,858  

SL Liquidity Series, LLC, Money Market Series,
0.25%(i)(j)(k)

     187,003       187,077  
   

 

 

  

Total Short-Term Securities — 1.3%
(Cost: $6,434,933)

 

     6,434,935  
   

 

 

  

Total Investments Before Options Written — 101.2%
(Cost: $313,457,054)

 

     505,531,727  
   

 

 

  

Options Written — (1.2)%
(Premiums Received: $(5,767,781))

 

     (6,168,025 ) 
   

 

 

  

Total Investments, Net of Options Written — 100.0%
(Cost: $307,689,273)

 

     499,363,702  

Other Assets Less Liabilities — 0.0%

 

     225,477  
   

 

 

  

Net Assets — 100.0%

 

   $ 499,589,179  
   

 

 

  

 

(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) 

Non-income producing security.

(c) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(d) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $7,354,149, representing 1.47% of its net assets as of period end, and an original cost of $3,238,780.

(e) 

All or a portion of this security is on loan.

(f) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(g) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(h) 

Zero-coupon bond

(i) 

Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.

(j) 

Affiliate of the Trust.

(k)

Annualized 7-day yield as of period end.

(l) 

All or a portion of this security was purchased with the cash collateral from loaned securities.

 

 

 

2  

    

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the period ended September 30, 2020, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer    Value at
12/31/19		      Purchases
at Cost		      Proceeds
from
Sales		      Net
Realized
Gain
(Loss)		      Change in
Unrealized
Appreciation
(Depreciation)		      Value at
09/30/20		      Shares
Held at
09/30/20		      Income      Capital Gain
Distributions
from
Underlying
Funds		  

BlackRock Liquidity Funds, T-Fund, Institutional Class

    $ 3,489,138$         2,758,720 (a)     $ —      $ —      $ —      $ 6,247,858        6,247,858      $ 30,789      $ —  

SL Liquidity Series, LLC, Money Market Series

      253,877        —        (66,435 )(a)       (363 )       (2 )       187,077        187,003        7,259 (b)       —  
           

 

 

     

 

 

     

 

 

        

 

 

     

 

 

  
            $ (363 )     $ (2 )     $ 6,434,935         $ 38,048      $ —  
           

 

 

     

 

 

     

 

 

        

 

 

     

 

 

  

 

  (a) 

Represents net amount purchased (sold).

 
  (b) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts		        Expiration
Date		        Exercise
Price		       

Notional

Amount (000)

        Value  
Call                                                   

Abbott Laboratories

      174          10/02/20        USD     103.00        USD     1,894        $ (103,095 ) 

AmerisourceBergen Corp

      27          10/02/20        USD     98.50        USD     262          (1,013 ) 

Amgen, Inc

      58          10/02/20        USD     242.50        USD     1,474          (75,835 ) 

Becton Dickinson and Co

      49          10/02/20        USD     265.00        USD     1,140          (6,125 ) 

Biogen, Inc

      18          10/02/20        USD     287.50        USD     511          (2,430 ) 

Boston Scientific Corp

      190          10/02/20        USD     40.50        USD     726          (760 ) 

Johnson & Johnson

      123          10/02/20        USD     152.50        USD     1,831          (1,169 ) 

Masimo Corp

      116          10/02/20        USD     229.00        USD     2,738          (89,074 ) 

Medtronic PLC

      95          10/02/20        USD     102.00        USD     987          (17,432 ) 

Regeneron Pharmaceuticals, Inc

      4          10/02/20        USD     630.00        USD     224          (110 ) 

Sarepta Therapeutics, Inc

      17          10/02/20        USD     157.50        USD     239          (2,550 ) 

Teladoc Health, Inc

      52          10/02/20        USD     230.00        USD     1,140          (4,290 ) 

UnitedHealth Group, Inc

      145          10/02/20        USD     317.50        USD     4,521          (13,775 ) 

Vertex Pharmaceuticals, Inc

      22          10/02/20        USD     280.00        USD     599          (1,100 ) 

Vertex Pharmaceuticals, Inc

      11          10/02/20        USD     267.50        USD     299          (5,555 ) 

Zoetis, Inc

      91          10/02/20        USD     160.00        USD     1,505          (48,230 ) 

Abbott Laboratories

      219          10/09/20        USD     116.00        USD     2,383          (8,322 ) 

Alexion Pharmaceuticals, Inc

      31          10/09/20        USD     109.00        USD     355          (20,460 ) 

Anthem, Inc

      75          10/09/20        USD     282.50        USD     2,014          (6,938 ) 

Anthem, Inc

      74          10/09/20        USD     272.50        USD     1,988          (28,120 ) 

Baxter International, Inc

      240          10/09/20        USD     88.00        USD     1,930          (2,400 ) 

Baxter International, Inc

      62          10/09/20        USD     84.00        USD     499          (930 ) 

Becton Dickinson and Co

      24          10/09/20        USD     242.50        USD     558          (1,500 ) 

Bristol-Myers Squibb Co

      237          10/09/20        USD     63.00        USD     1,429          (2,133 ) 

Cardinal Health, Inc

      98          10/09/20        USD     51.00        USD     460          (980 ) 

Centene Corp

      2          10/09/20        USD     64.00        USD     12          (32 ) 

Edwards Lifesciences Corp

      1          10/09/20        USD     86.50        USD     8          (35 ) 

Humana, Inc

      23          10/09/20        USD     425.00        USD     952          (7,475 ) 

Humana, Inc

      19          10/09/20        USD     407.50        USD     786          (23,560 ) 

Illumina, Inc

      35          10/09/20        USD     357.50        USD     1,082          (2,100 ) 

Intuitive Surgical, Inc

      12          10/09/20        USD     730.00        USD     851          (10,920 ) 

Johnson & Johnson

      142          10/09/20        USD     150.00        USD     2,114          (19,241 ) 

Medtronic PLC

      190          10/09/20        USD     105.51        USD     1,974          (17,936 ) 

Pfizer, Inc

      155          10/09/20        USD     38.50        USD     569          (1,783 ) 

PPD, Inc

      237          10/09/20        USD     32.25        USD     877          (113,082 ) 

Regeneron Pharmaceuticals, Inc

      12          10/09/20        USD     570.00        USD     672          (12,420 ) 

Sarepta Therapeutics, Inc

      17          10/09/20        USD     157.50        USD     239          (1,870 ) 

 

 

SCHEDULE OF INVESTMENTS

   3

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts		        Expiration
Date		        Exercise
Price		       

Notional

Amount (000)

        Value  
Call (continued)                                                   

UnitedHealth Group, Inc

      140          10/09/20        USD     315.00        USD     4,365        $ (51,170 ) 

Vertex Pharmaceuticals, Inc

      91          10/09/20        USD     287.50        USD     2,476          (8,873 ) 

Abbott Laboratories

      189          10/16/20        USD     110.00        USD     2,057          (33,736 ) 

ABIOMED, Inc

      21          10/16/20        USD     280.00        USD     582          (16,590 ) 

Acceleron Pharma, Inc

      58          10/16/20        USD     100.00        USD     653          (75,980 ) 

Agilent Technologies, Inc

      55          10/16/20        USD     100.00        USD     555          (14,025 ) 

Agios Pharmaceuticals, Inc

      50          10/16/20        USD     45.00        USD     175          (625 ) 

Alcon AG

      230          10/16/20        USD     60.00        USD     1,310          (9,200 ) 

Alexion Pharmaceuticals, Inc

      1          10/16/20        USD     120.00        USD     11          (268 ) 

Allakos, Inc

      37          10/16/20        USD     100.00        USD     301          (18,500 ) 

Alnylam Pharmaceuticals, Inc

      64          10/16/20        USD     150.00        USD     932          (22,400 ) 

Amedisys, Inc

      3          10/16/20        USD     250.00        USD     71          (773 ) 

Amgen, Inc

      57          10/16/20        USD     250.00        USD     1,449          (47,167 ) 

Apellis Pharmaceuticals, Inc

      45          10/16/20        USD     30.80        USD     136          (6,227 ) 

Arena Pharmaceuticals, Inc

      58          10/16/20        USD     70.00        USD     434          (36,250 ) 

Avantor, Inc

      265          10/16/20        USD     22.50        USD     596          (21,862 ) 

Biogen, Inc

      25          10/16/20        USD     285.00        USD     709          (14,500 ) 

BioMarin Pharmaceutical, Inc

      138          10/16/20        USD     80.00        USD     1,050          (15,870 ) 

Blueprint Medicines Corp

      19          10/16/20        USD     80.00        USD     176          (25,460 ) 

Boston Scientific Corp

      322          10/16/20        USD     41.00        USD     1,230          (3,864 ) 

ChemoCentryx, Inc

      10          10/16/20        USD     75.00        USD     55          (1,925 ) 

ChemoCentryx, Inc

      10          10/16/20        USD     70.00        USD     55          (2,525 ) 

Cigna Corp

      75          10/16/20        USD     195.00        USD     1,271          (1,350 ) 

Dicerna Pharmaceuticals, Inc

      30          10/16/20        USD     22.50        USD     54          (900 ) 

Eidos Therapeutics, Inc

      32          10/16/20        USD     50.00        USD     162          (8,640 ) 

FibroGen, Inc

      23          10/16/20        USD     47.50        USD     95          (10,350 ) 

Galapagos NV, ADR

      11          10/16/20        USD     155.00        USD     156          (2,173 ) 

Genmab A/S, ADR

      150          10/16/20        USD     40.00        USD     549          (4,500 ) 

GoodRx Holdings, Inc., Class A

      12          10/16/20        USD     65.00        USD     67          (1,950 ) 

Immunomedics, Inc

      92          10/16/20        USD     48.00        USD     782          (345,000 ) 

Intellia Therapeutics, Inc

      27          10/16/20        USD     25.00        USD     54          (945 ) 

Intuitive Surgical, Inc

      15          10/16/20        USD     760.00        USD     1,064          (12,000 ) 

Iovance Biotherapeutics, Inc

      62          10/16/20        USD     30.00        USD     204          (26,660 ) 

IQVIA Holdings, Inc

      51          10/16/20        USD     160.00        USD     804          (13,387 ) 

Johnson & Johnson

      160          10/16/20        USD     155.00        USD     2,382          (11,760 ) 

Kodiak Sciences, Inc

      13          10/16/20        USD     50.00        USD     77          (13,455 ) 

LHC Group, Inc

      17          10/16/20        USD     210.00        USD     361          (11,815 ) 

Livongo Health, Inc

      35          10/16/20        USD     140.00        USD     490          (26,075 ) 

Masimo Corp

      16          10/16/20        USD     240.00        USD     378          (9,360 ) 

Medtronic PLC

      34          10/16/20        USD     110.00        USD     353          (901 ) 

Merck & Co., Inc

      153          10/16/20        USD     87.50        USD     1,269          (2,295 ) 

Mersana Therapeutics, Inc

      114          10/16/20        USD     25.00        USD     212          (3,135 ) 

Mirati Therapeutics, Inc

      11          10/16/20        USD     145.00        USD     183          (28,710 ) 

MyoKardia, Inc

      13          10/16/20        USD     110.00        USD     177          (34,905 ) 

MyoKardia, Inc

      13          10/16/20        USD     130.00        USD     177          (13,260 ) 

Nektar Therapeutics

      49          10/16/20        USD     19.50        USD     81          (1,225 ) 

Neurocrine Biosciences, Inc

      70          10/16/20        USD     115.00        USD     673          (2,450 ) 

Nevro Corp

      26          10/16/20        USD     135.00        USD     362          (20,540 ) 

Pfizer, Inc

      295          10/16/20        USD     37.00        USD     1,083          (20,502 ) 

PPD, Inc

      80          10/16/20        USD     35.00        USD     296          (21,200 ) 

Prothena Corp. PLC

      84          10/16/20        USD     11.00        USD     84          (2,310 ) 

Quest Diagnostics, Inc

      2          10/16/20        USD     120.00        USD     23          (175 ) 

ResMed, Inc

      50          10/16/20        USD     185.00        USD     857          (3,750 ) 

Royalty Pharma PLC, Class A

      31          10/16/20        USD     50.00        USD     130          (620 ) 

Sanofi, ADR

      152          10/16/20        USD     50.00        USD     763          (19,380 ) 

Seattle Genetics, Inc

      127          10/16/20        USD     170.00        USD     2,485          (337,820 ) 

Seattle Genetics, Inc

      124          10/16/20        USD     180.00        USD     2,427          (216,380 ) 

Selectquote, Inc

      13          10/16/20        USD     25.00        USD     26          (130 ) 

Silk Road Medical, Inc

      9          10/16/20        USD     55.00        USD     60          (10,980 ) 

Stryker Corp

      118          10/16/20        USD     195.00        USD     2,459          (173,460 ) 

TCR2 Therapeutics, Inc

      20          10/16/20        USD     22.50        USD     41          (1,350 ) 

Teleflex, Inc

      38          10/16/20        USD     380.00        USD     1,294          (5,700 ) 

 

 

4  

    

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts		        Expiration
Date		        Exercise
Price		       

Notional

Amount (000)

        Value  
Call (continued)                                                   

Thermo Fisher Scientific, Inc

      150          10/16/20        USD     440.00        USD     6,623        $ (148,500 ) 

Vir Biotechnology, Inc

      29          10/16/20        USD     55.00        USD     100          (435 ) 

Zimmer Biomet Holdings, Inc

      111          10/16/20        USD     150.00        USD     1,511          (5,550 ) 

Amgen, Inc

      44          10/23/20        USD     257.50        USD     1,118          (29,370 ) 

Baxter International, Inc

      55          10/23/20        USD     83.50        USD     442          (3,988 ) 

Becton Dickinson and Co

      50          10/23/20        USD     245.00        USD     1,163          (9,125 ) 

Boston Scientific Corp

      360          10/23/20        USD     43.00        USD     1,376          (10,440 ) 

Bristol-Myers Squibb Co

      91          10/23/20        USD     60.00        USD     549          (12,240 ) 

Cardinal Health, Inc

      4          10/23/20        USD     50.00        USD     19          (170 ) 

Centene Corp

      145          10/23/20        USD     59.50        USD     846          (24,940 ) 

Cigna Corp

      72          10/23/20        USD     172.50        USD     1,220          (28,980 ) 

Eli Lilly & Co

      86          10/23/20        USD     155.00        USD     1,273          (9,890 ) 

Humana, Inc

      19          10/23/20        USD     407.50        USD     786          (31,255 ) 

Humana, Inc

      18          10/23/20        USD     402.50        USD     745          (35,280 ) 

Intuitive Surgical, Inc

      17          10/23/20        USD     720.00        USD     1,206          (41,225 ) 

Johnson & Johnson

      82          10/23/20        USD     152.50        USD     1,221          (14,965 ) 

Medtronic PLC

      125          10/23/20        USD     110.00        USD     1,299          (8,000 ) 

Merck & Co., Inc

      154          10/23/20        USD     85.50        USD     1,277          (12,089 ) 

Pfizer, Inc

      294          10/23/20        USD     38.00        USD     1,079          (17,052 ) 

UnitedHealth Group, Inc

      57          10/23/20        USD     317.50        USD     1,777          (38,475 ) 

Vertex Pharmaceuticals, Inc

      42          10/23/20        USD     277.50        USD     1,143          (28,350 ) 

Abbott Laboratories

      362          10/30/20        USD     104.00        USD     3,940          (280,550 ) 

AmerisourceBergen Corp

      30          10/30/20        USD     99.50        USD     291          (7,650 ) 

Baxter International, Inc

      145          10/30/20        USD     82.00        USD     1,166          (29,362 ) 

Boston Scientific Corp

      201          10/30/20        USD     40.00        USD     768          (16,080 ) 

Bristol-Myers Squibb Co

      170          10/30/20        USD     60.00        USD     1,025          (25,500 ) 

Centene Corp

      188          10/30/20        USD     57.00        USD     1,097          (66,740 ) 

Cigna Corp

      65          10/30/20        USD     167.50        USD     1,101          (50,050 ) 

Edwards Lifesciences Corp

      315          10/30/20        USD     79.50        USD     2,514          (92,925 ) 

Eli Lilly & Co

      129          10/30/20        USD     152.50        USD     1,909          (35,152 ) 

Gilead Sciences, Inc

      304          10/30/20        USD     64.00        USD     1,921          (60,040 ) 

Humana, Inc

      21          10/30/20        USD     410.00        USD     869          (35,490 ) 

Humana, Inc

      18          10/30/20        USD     400.00        USD     745          (42,210 ) 

Johnson & Johnson

      61          10/30/20        USD     152.50        USD     908          (12,475 ) 

Medtronic PLC

      23          10/30/20        USD     104.00        USD     239          (7,107 ) 

Merck & Co., Inc

      107          10/30/20        USD     85.00        USD     888          (17,066 ) 

Regeneron Pharmaceuticals, Inc

      33          10/30/20        USD     590.00        USD     1,847          (39,270 ) 

UnitedHealth Group, Inc

      65          10/30/20        USD     322.50        USD     2,026          (39,000 ) 

Zoetis, Inc

      126          10/30/20        USD     162.50        USD     2,084          (73,710 ) 

Boston Scientific Corp

      201          11/06/20        USD     38.50        USD     768          (40,501 ) 

Eli Lilly & Co

      88          11/06/20        USD     152.50        USD     1,303          (29,964 ) 

Intuitive Surgical, Inc

      12          11/06/20        USD     700.00        USD     851          (52,560 ) 

Johnson & Johnson

      61          11/06/20        USD     155.00        USD     908          (12,017 ) 

McKesson Corp

      24          11/06/20        USD     155.00        USD     357          (12,240 ) 

Medtronic PLC

      95          11/06/20        USD     105.00        USD     987          (33,487 ) 

Pfizer, Inc

      552          11/06/20        USD     38.00        USD     2,026          (55,752 ) 

ABIOMED, Inc

      21          11/20/20        USD     290.00        USD     582          (33,390 ) 

Acceleron Pharma, Inc

      94          11/20/20        USD     110.00        USD     1,058          (97,290 ) 

Agios Pharmaceuticals, Inc

      50          11/20/20        USD     45.00        USD     175          (3,625 ) 

Alexion Pharmaceuticals, Inc

      75          11/20/20        USD     135.00        USD     858          (21,375 ) 

Allakos, Inc

      87          11/20/20        USD     85.00        USD     709          (75,690 ) 

Allogene Therapeutics, Inc

      123          11/20/20        USD     35.00        USD     464          (58,425 ) 

Amedisys, Inc

      73          11/20/20        USD     240.00        USD     1,726          (106,580 ) 

Amgen, Inc

      61          11/20/20        USD     255.00        USD     1,550          (77,165 ) 

Apellis Pharmaceuticals, Inc

      44          11/20/20        USD     35.00        USD     133          (7,700 ) 

Arena Pharmaceuticals, Inc

      17          11/20/20        USD     80.00        USD     127          (14,025 ) 

Blueprint Medicines Corp

      19          11/20/20        USD     85.00        USD     176          (22,895 ) 

Boston Scientific Corp

      190          11/20/20        USD     40.00        USD     726          (22,420 ) 

Bristol-Myers Squibb Co

      170          11/20/20        USD     65.00        USD     1,025          (12,835 ) 

Dicerna Pharmaceuticals, Inc

      30          11/20/20        USD     22.50        USD     54          (2,325 ) 

Edwards Lifesciences Corp

      312          11/20/20        USD     85.00        USD     2,490          (70,980 ) 

Encompass Health Corp

      160          11/20/20        USD     70.00        USD     1,040          (28,800 ) 

 

 

SCHEDULE OF INVESTMENTS

   5

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts		        Expiration
Date		        Exercise
Price		       

Notional

Amount (000)

        Value  
Call (continued)                                                   

Galapagos NV, ADR

      12          11/20/20        USD     155.00        USD     170        $ (7,800 ) 

Genmab A/S, ADR

      24          11/20/20        USD     40.00        USD     88          (3,840 ) 

GoodRx Holdings, Inc., Class A

      11          11/20/20        USD     70.00        USD     61          (4,455 ) 

Halozyme Therapeutics, Inc

      103          11/20/20        USD     30.00        USD     271          (8,755 ) 

Illumina, Inc

      21          11/20/20        USD     290.00        USD     649          (67,515 ) 

Incyte Corp

      94          11/20/20        USD     95.00        USD     844          (39,010 ) 

Intellia Therapeutics, Inc

      27          11/20/20        USD     25.00        USD     54          (13,500 ) 

Iovance Biotherapeutics, Inc

      61          11/20/20        USD     37.00        USD     201          (7,154 ) 

LHC Group, Inc

      45          11/20/20        USD     210.00        USD     956          (65,475 ) 

Mersana Therapeutics, Inc

      114          11/20/20        USD     30.00        USD     212          (14,820 ) 

Mirati Therapeutics, Inc

      10          11/20/20        USD     165.00        USD     166          (25,950 ) 

Molecular Templates, Inc

      21          11/20/20        USD     15.00        USD     23          (840 ) 

Nektar Therapeutics

      49          11/20/20        USD     22.00        USD     81          (2,328 ) 

Neurocrine Biosciences, Inc

      39          11/20/20        USD     120.00        USD     375          (3,705 ) 

Nevro Corp

      27          11/20/20        USD     145.00        USD     376          (24,300 ) 

Quest Diagnostics, Inc

      50          11/20/20        USD     125.00        USD     572          (10,875 ) 

Sanofi, ADR

      66          11/20/20        USD     52.76        USD     331          (8,190 ) 

Selectquote, Inc

      26          11/20/20        USD     25.00        USD     53          (1,625 ) 

Seres Therapeutics, Inc

      52          11/20/20        USD     30.00        USD     147          (17,680 ) 

Silk Road Medical, Inc

      28          11/20/20        USD     70.50        USD     188          (12,969 ) 

Stryker Corp

      120          11/20/20        USD     220.00        USD     2,500          (58,800 ) 

Teleflex, Inc

      57          11/20/20        USD     360.00        USD     1,940          (70,110 ) 

UnitedHealth Group, Inc

      54          11/20/20        USD     310.00        USD     1,684          (91,395 ) 
                          

 

 

  
                           $ (5,397,896 ) 
                          

 

 

  

OTC Options Written

 

Description    Counterparty    Number of
Contracts		      Expiration
Date		     

Exercise

Price

     

Notional

Amount (000)

      Value  
Call                                                

Genmab A/S, ADR

    UBS AG      2,700        10/07/20      DKK     2,358.99      DKK     6,222      $ (9,951 ) 

Merck KGaA

    Credit Suisse International      5,100        10/07/20      EUR     118.04      EUR     634        (39,451 ) 

Passage Bio, Inc

    JPMorgan Chase Bank N.A.      1,600        10/07/20      USD     16.67      USD     21        (32 ) 

Straumann Holding AG, Registered Shares

    Barclays Bank PLC      1,000        10/07/20      CHF     941.20      CHF     932        (10,042 ) 

Sanofi

    Barclays Bank PLC      8,300        10/15/20      EUR     90.53      EUR     709        (2,156 ) 

Rapt Therapeutics, Inc

    Credit Suisse International      3,400        10/19/20      USD     25.75      USD     110        (24,024 ) 

Eisai Co. Ltd

    Morgan Stanley & Co. International PLC      6,100        10/20/20      JPY     9,699.04      JPY     58,757        (16,877 ) 

Hansoh Pharmaceutical Group Ltd

    JPMorgan Chase Bank N.A.      100,000        10/20/20      HKD     37.05      HKD     3,788        (20,440 ) 

Molecular Templates, Inc

    Credit Suisse International      6,300        10/21/20      USD     12.54      USD     69        (1,098 ) 

Seres Therapeutics, Inc

    Credit Suisse Securities (USA) LLC      5,200        10/21/20      USD     26.66      USD     147        (16,973 ) 

TCR2 Therapeutics, Inc

    Credit Suisse International      2,000        10/21/20      USD     19.39      USD     41        (4,079 ) 

AstraZeneca PLC

    Barclays Bank PLC      4,000        10/22/20      GBP     84.37      GBP     339        (14,399 ) 

Sanofi

    Credit Suisse International      7,900        10/22/20      EUR     88.96      EUR     675        (7,083 ) 

WuXi AppTec Co. Ltd., Class H

    Citibank N.A.      30,500        10/22/20      HKD     111.47      HKD     3,418        (20,516 ) 

Eisai Co. Ltd

    Morgan Stanley & Co. International PLC      6,100        10/23/20      JPY     9,699.04      JPY     58,757        (18,211 ) 

Alcon AG

    Credit Suisse International      23,100        10/28/20      USD     59.95      USD     1,316        (22,783 ) 

Alnylam Pharmaceuticals, Inc

    Citibank N.A.      6,300        10/28/20      USD     134.39      USD     917        (83,300 ) 

Avantor, Inc

    Credit Suisse International      25,900        10/28/20      USD     23.01      USD     583        (28,748 ) 

IQVIA Holdings, Inc

    UBS AG      5,100        10/28/20      USD     161.92      USD     804        (22,580 ) 

Kodiak Sciences, Inc

    Credit Suisse International      2,300        10/28/20      USD     59.67      USD     136        (9,083 ) 

LHC Group, Inc

    Credit Suisse International      1,800        10/28/20      USD     202.88      USD     383        (27,360 ) 

Masimo Corp

    Credit Suisse International      1,500        10/28/20      USD     229.00      USD     354        (19,180 ) 

Oak Street Health, Inc

    JPMorgan Chase Bank N.A.      3,300        10/28/20      USD     44.94      USD     176        (31,299 ) 

Relay Therapeutics, Inc

    Morgan Stanley & Co. International PLC      4,300        10/28/20      USD     46.80      USD     183        (10,794 ) 

WuXi AppTec Co. Ltd., Class H

    Morgan Stanley & Co. International PLC      46,000        10/28/20      HKD     113.56      HKD     5,155        (28,624 ) 

Arcutis Biotherapeutics, Inc

    Bank of America N.A.      1,100        11/02/20      USD     25.49      USD     32        (5,090 ) 

Passage Bio, Inc

    JPMorgan Chase Bank N.A.      1,600        11/02/20      USD     17.07      USD     21        (577 ) 

ResMed, Inc

    UBS AG      5,100        11/02/20      USD     192.25      USD     874        (6,494 ) 

Krystal Biotech, Inc

    Credit Suisse International      2,000        11/03/20      USD     48.64      USD     86        (2,713 ) 

Merck KGaA

    Credit Suisse International      4,900        11/03/20      EUR     126.48      EUR     609        (18,814 ) 

 

 

6  

    

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

 

OTC Options Written (continued)

 

Description    Counterparty    Number of
Contracts		      Expiration
Date		     

Exercise

Price

     

Notional

Amount (000)

      Value  
Call (continued)                                                    

AstraZeneca PLC

    Morgan Stanley & Co. International PLC      2,400        11/04/20        GBP       87.93        GBP       203      $ (7,492 ) 

Genmab A/S, ADR

    Goldman Sachs International      3,200        11/04/20        DKK       2,326.11        DKK       7,374        (33,911 ) 

Hansoh Pharmaceutical Group Ltd

    Citibank N.A.      162,000        11/04/20        HKD       38.71        HKD       6,137        (24,012 ) 

Rogers Corp

    UBS AG      2,100        11/04/20        CHF       342.10        CHF       663        (2,921 ) 

Sanofi

    Goldman Sachs International      11,100        11/04/20        EUR       89.50        EUR       949        (10,787 ) 

Annexon, Inc

    JPMorgan Chase Bank N.A.      6,700        11/06/20        USD       29.75        USD       203        (23,007 ) 

Rogers Corp

    UBS AG      2,900        11/06/20        CHF       347.26        CHF       915        (3,730 ) 

Royalty Pharma PLC, Class A

    JPMorgan Chase Bank N.A.      3,000        11/06/20        USD       41.70        USD       126        (9,146 ) 

WuXi AppTec Co. Ltd., Class H

    JPMorgan Chase Bank N.A.      13,800        11/10/20        HKD       112.97        HKD       1,547        (9,737 ) 

Wuxi Biologics Cayman, Inc

    JPMorgan Chase Bank N.A.      48,000        11/10/20        HKD       192.19        HKD       9,117        (65,948 ) 

Arcutis Biotherapeutics, Inc

    Citibank N.A.      15,800        11/11/20        USD       30.45        USD       463        (14,255 ) 

Envista Holdings Corp

    JPMorgan Chase Bank N.A.      14,600        11/16/20        USD       26.50        USD       360        (9,632 ) 

Hansoh Pharmaceutical Group Ltd

    Morgan Stanley & Co. International PLC      90,000        11/19/20        HKD       38.78        HKD       3,409        (11,336 ) 

Immunovant, Inc

    JPMorgan Chase Bank N.A.      14,300        11/23/20        USD       40.00        USD       503        (21,444 ) 
                     

 

 

  
                      $ (770,129 ) 
                     

 

 

  

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

 

  •  

Level 1 — Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access

 

  •  

Level 2 — Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs)

 

  •  

Level 3 — Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the BlackRock Global Valuation Methodologies Committee’s (the “Global Valuation Committee’s”) assumptions used in determining the fair value of financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Global Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust’s policy regarding valuation of financial instruments, refer to its most recent financial statements.

Certain investments of the Trust were fair valued using net asset value (“NAV”) per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

The following tables summarize the Trust’s investments and derivative financial instruments categorized in the disclosure hierarchy. The breakdown of the Trust’s investments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                  

Investments

                  

Long-Term Investments

                  

Common Stocks

                  

Biotechnology

    $ 96,587,511        $ 5,357,574        $ 2,294,537        $ 104,239,622  

Diversified Financial Services

      1,862,269          —          —          1,862,269  

Health Care Equipment & Supplies

      148,398,009          3,179,180          —          151,577,189  

Health Care Providers & Services

      89,031,008          2,821,669          —          91,852,677  

Health Care Technology

      4,462,342          —          —          4,462,342  

Insurance

      674,527          —          —          674,527  

Life Sciences Tools & Services

      32,133,715          6,218,245          —          38,351,960  

Pharmaceuticals

      79,459,243          23,791,542          —          103,250,785  

 

 

SCHEDULE OF INVESTMENTS

   7

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

 

Fair Value Hierarchy as of Period End (continued)

 

      Level 1        Level 2        Level 3        Total  

Corporate Bonds

    $ —        $ —        $ 260,000        $ 260,000  

Other Interests

      —          —          252,913          252,913  

Preferred Securities

                  

Preferred Stocks

      —          1,896,843          415,665          2,312,508  

Short-Term Securities

                  

Money Market Funds

      6,247,858          —          —          6,247,858  
  

 

 

       

 

 

       

 

 

       

 

 

  
   $ 458,856,482        $ 43,265,053        $ 3,223,115          505,344,650  
  

 

 

       

 

 

       

 

 

       

 

 

  

Investments Valued at NAV(a)

                     187,077  
                 

 

 

  
                  $ 505,531,727  
                 

 

 

  

Derivative Financial Instruments(b)

                  

Liabilities

                  

Equity Contracts

    $ (5,143,264 )       $ (1,024,761 )       $ —        $ (6,168,025 ) 
  

 

 

       

 

 

       

 

 

       

 

 

  

 

  (a) 

Certain investments of the Trust were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

 
  (b) 

Derivative financial instruments are options written. Options written are shown at value.

 

 

 

8  

    

Schedule of Investments  (unaudited) (continued)

September 30, 2020

   

BlackRock Health Sciences Trust (BME)

 

Currency Abbreviation
CHF    Swiss Franc
DKK    Danish Krone
EUR    Euro
GBP    British Pound
HKD    Hong Kong Dollar
JPY    Japanese Yen
USD    United States Dollar

 

Portfolio Abbreviation
ADR    American Depositary Receipt
OTC    Over-the-Counter

 

 

SCHEDULE OF INVESTMENTS

   9